Survival and Clinical Trial Design

Tarceva (erlotinib) in combination with gemcitabine is indicated for first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Here you can find details concerning recently completed trial for Pancreatic Cancer. You can also read about survival and other efficacy results.